In this section


The Monash Health Department of Oncology provides more than 1.5 million residents of southern Melbourne with access to world leading cancer treatment over four locations within the Monash Health service:

Moorabbin Hospital: Breast cancer, GI cancer, GU cancer, Lung cancer, Head & Neck cancer, Gynecological cancer, Urologic cancer

Dandenong Hospital: General Oncology, Geriatric Oncology

Casey Hospital: General Oncology

Monash Health Translation Precinct (MHTP building Level 3). Monash Medical Centre, Clayton: Cancer Clinical Trials

Monash Medical Centre Clayton: Neuro-oncology (Brain Cancer)

Our Services

Cancer patients receive care from diagnosis to treatment and follow-up support. Through collaborative multidisciplinary team framework we provide the Medical Oncology aspect of cancer care, integrating with teams from surgical and radiation oncology and Palliative and Supportive care.

Our Staff

Department Head

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP
Professor/Director of Oncology
Gastrointestinal Cancers Neuroendocrine Tumours 

Senior Leadership Team

A/Prof. Arun Azad MBBS FRACP PhD
Head of Oncology Trials
Genitourinary Cancer

A/Prof. Jake Shortt BMedSc MBChB FRACP FRCPA PhD
Head of Translational Research, Haematologist

Senior Medical Staff

Dr. Muhammad Alamgeer MBBS MD MRCP FRACP
Head and Neck Cancer

Dr. Peter Briggs MBBS FRACP
Lung Cancer

Dr. Puey Ling Chia MBBS MRCP FRACP
Medical Oncologist (Locum Casey Hospital)

Dr. Daphne Day MBBS (Hons), FRACP
Breast, Head and Neck Cancer and Phase 1 trials

A/Prof. Michael Franco MBBS FRACP FAChPM
Palliative Medicine, Breast and Gastrointestinal Cancer

Dr. Sophia Frentzas MBBS BSc (Hons) MRCP (UK) PHD MRCP (Med Onc UK) PGDip (Oncology) FRACP
Gastrointestinal, Breast and Gynaecological Cancer

Dr. Geraldine Goss MBBS FRACP MD MMED
Gynaecological Cancer

A/Prof. Marion Harris MBBS FRACP
Director of Familial Cancer, Gastrointestinal and Breast Cancer

Dr. Edmond Kwan MBBS FRACP
Genitourinary Cancer

Palliative Medicine and Breast Cancer

Dr. Ben Markman MBBS FRACP
Phase 1 Trials, Lung, Gastrointestinal Cancer

Dr. Sagun Parakh BSc MbChB FRACP
Phase 1 Trials, Lung Cancer and Neuro-Oncology

Dr. David Pook BMedSci (Hons) MBBS FRACP MD
Genitourinary Cancer

Dr. Ranjana Srivastava MBBS FRACP
Breast, Gastrointestinal Cancer, Geriatric Oncology

A/Prof. Andrew Strickland MBBS FRACP
Gastrointestinal Cancer

Dr. Michelle White MBBS GDipPallMed FRACP
Breast Cancer

Support and Administration Staff

Ms. Annette McClellan
Oncology Department Secretary/PA to Professor Segelov.
P: +61 3 8572 2392

Ms. Sarah Niazmand
Oncology Research Administration Assistant
P: +61 3 8572 2390 or +61 3 8572 22021

Clinical Trials Fellows

Dr. Chun Gan MBBS

Dr. Siddharth Menon MBBS

Advanced Trainees 

Dr. Adithya Balasubramanian

Dr. Caroline Lum

Dr. Gabrielle Lie

Clinical Trials Research Staff

Ms. Karen Gillett
Oncology Research Manager

Ms. Merylyn Ryan
Oncology Research Operations Manager


Ms. Kim Brewin
Study Coordinator

Ms. Lauren Curtain
Study Coordinator

Early Phase

Ms. Cheryl-Ann Hawkins
Study Coordinator

Ms. Chris Brooks
Study Coordinator

Ms. Penny McGuire
Study Coordinator

Ms. Isabelle Nehma
Study Coordinator

Lung & Other

Ms. Laima Muceneikas
Study Coordinator

Ms. Lindsay Thompson
Study Coordinator

Gastrointestinal (GI)

Ms. Felicity McLeay
Study Coordinator

Ms. Chris Poole
Study Coordinator

Genitourinary (GU)

Ms. Linda Garrett
Study Coordinator

Ms. Louise Davis
Study Coordinator

Ms. Stephanie Kaladis
Study Coordinator


Ms. Sabah Saad
Ethics Submission Specialist

Clinical Trials Assistants

Ms. Deborah Chang
Clinical Trial Assistant

Ms. Kristy Horvath
Clinical Trial Assistant

Ms. Julie Kavanagh
Clinical Trial Assistant

Ms. Michelle Zheng
Clinical Trial Assistant

Laboratory Assistants

Ms. Susan Alford
Laboratory Assistant

Ms. Dixita Desai
Laboratory Assistant

Nurse Practitioners

Ms. Gillian Kruss - Metastatic Breast Cancer

Ms. Vicki McLeod

Translational Research Staff

Gastrointestinal Cancer Research Group

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP
Group Leader

Dr. Maja Green PhD, MSc,BSc (Hons)
Post Doctoral Fellow

Dr. Daphne Day MBBS (Hons), FRACP
PhD Student

Dr. Sameer Greenall PhD, BSc (Hons)
Research Fellow

Mr. Cameron Naidu MBBS
Honours Student

Prostate Cancer Therapeutics Research Group

A/Prof. Arun Azad MBBS FRACP PhD
Group Leader

Dr. Sarah To PhD BSc (Hons)
NHMRC CJ MArtin Post Doctoral Fellow

Ms Patrica Bukczynska BSc
Senior Research Assistant

Ms. Maria Docanto BSc (Hons)
Senior Research Assistant

Ms. Heidi Fettke BSc (Hons)
PhD Student

Dr. Edmond Kwan MBBS FRACP
PhD Student

Dr. Mark Waltham PhD BSc (Hons)
Research Scientist

Ms. Nicole Ng
Project Officer

Blood Cancer Therapeutics Research Group

A/Prof. Jake Shortt BMedSc MBChB FRACP FRCPA PhD
Group Leader

Dr Gareth Gregory MBBS (Hons) PhD FRACP FRCPA

Dr. Mark Waltham PhD BSc (Hons)
Research Scientist

Dr. Zahra Sabouri-Thompson MD PhD
Post Doctoral Fellow

Dr. Daniella Brasacchio
Research Fellow

Ms Belinda Maher BSc (Hons)
Research Assistant

Department Publications


J. Shapiro, S. Thayaneswaran, C. Underhill, K. Robledo, C. Karapetis, F. Day, L. Nott, J. Jefford, L. Chantrill, N. Pavlakis, N. Tebbutt, T. Price, M. Khasraw, G. V. Hazel, P. Waring, S. Tejpar, J. Simes, V. Gebski, J. Desai, E. Segelov. Cetuximab alone or with irinotecan for refractory KRAS-, NRAS-, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomised phase II ICECREAM study. Clinical Colorectal Cancer, 2018, Jun 8.

Singh S, Moody L, Chan D, Metz D, Strosberg J, Asmis T, Bailey D, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan S, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours. JAMA Oncology.

Tang M, Price T, Shapiro J, Gibbs P, Haller D, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. 2018. Targeted therapies for metastatic colorectal cancer. Expert Review in Anticancer Therapy accepted for publication 17 July 2018.

Tang M, Price JT, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis (2018). Expert Review of Anticancer Therapy. Volume 18(4), 339-349.


Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC, Segelov E. Recurrence in Resectable Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4(4): 583-585.

Sarah Q. To, Edmond M. Kwan, Heidi C. Fettke, Andrew Mant, Maria M. Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenho¨fer, Arun A. Azad. Expression of Androgen Receptor Splice Variant 7 or 9 in WholeBlood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer Eur Urol 2018. doi: 10.1016/j.eururo.2018.01.007. [Epub ahead of print]

Au L, Grant M, Haydon A, Segelov E, Antill Y, Oliva, Wilkins S, P McMurrick P, J Shapiro J. 2018. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: a cohort study of two cancer centres. International Journal of Surgery. 51:71-5.

Chi, W, Warner R, Chan D, Singh S, Segelov E, Strosberg J, Wisnivesky J, Kim M. 2018. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas. 47:321-25.

Chan DL, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-up for resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): A practice survey of the Commonwealth Neuroendocrine collaboration (CommNETs) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology, 2018.

Identification of a SiglecF+ Granulocyte-Macrophage Progenitor (GMP). Bolden J, Lucas E, Zhou G, O'Sullivan J, de Graf C, McKenzie M, Di Rago L, Baldin T, Shortt J, Alexander W, Bochner B, Ritchie ME, Hilton D, Fairfax K. J Leuk Biol2018 (accepted for publication).

Tumour lysis syndrome. Gregory GP, Shortt J. Textbook of palliative care 2018; In: MacLeod R, van den Block L. (eds). Springer, Cham.

Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Co-published in Int Med Jand Nephrology (accepted for publication).

A comprehensive protocol resource for performing pooled shRNA and CRISPR screens. Cluse LA, Nikolic I, Knight D, Madhamshettiwar PB, Luu J, Cowley KJ, Semple T, Arnau GM, Shortt J, Johnstone RW, Simpson KJ. Methods Mol Biol2018; 1725: 201-227.

Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. Ross D, Amerena J, Arthur C, Burbury K, Ko B, Mills T, Shortt J, Kostner K. Int Med J 2018; 48 Suppl 2: 5-13.

Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. Opat S, Hearps A, Thia K, Yuen A, Rogers B, Chachage M, Moore G, Shortt J, Ryland G, Blombery P, Schwarer A, Noori T, Trapani JA, Jaworowski A, Voskoboinik I. Blood2018; 131: 699-702.


Segelov E, Lordick F, Goldstein D, Chantrill L, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price T. 2017. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: Expert perspectives from the Australian Gastrointestinal Trials Group with invited international faculty. Expert Review in Anticancer Therapy. 17:951-64. First author, Impact factor 2

Annala M, Nappi L, Azad A, Mo F, Fazli L, Chi KN, Wyatt AW. Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical genitourinary cancer. 2017 Feb 1;15(1):e145-50.

Wein L, Rowe C, Brady B, Handolias D, Lipton L, Pook D, Stanley R, Haines I. Prevalence of systemic anticancer therapy for patients within the last 30 days of life: experience in a private hospital oncology group. Internal medicine journal. 2017 Mar 1;47(3):280-3.

Srivastava R. The Interpreter. N Engl J Med. 2017 Mar 2;376:812-3

Chan DLH, Segelov E, Wong RSH, Smith A, Herbertson RA, Li B, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2017 Issue 6, Art: CD007047. Contributing author, impact factor 6.1

Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, Kwan EM, Fox S, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal M, Desai J. (in press). Precision medicine using a clinician-directed, tailored approach to molecular profiling. Asia Pac J Clin Oncol. doi: 10.1111/ajco.12787

Chan D, Segelov E, Ferone D, Albertelli M, Pavlakis N, Singh S. 2017. Escalated dose somatostatin analogues for anti-proliferative effect in GEP-NETS: A systematic review. Endocrine. 57:366-75. contributing author, Impact factor 3.1

Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, Segelov E. 2017. Uncommon anal neoplasms in Surgical Clinics of North America. Surgical Oncology Clinics of North America 26:143-61. Invited chapter editor and Senior author, Impact factor 2

Chan D, Segelov E, Singh S. 2017. Update on the use of everolimus in the management of metastatic neuroendocrine tumors of gastrointestinal origin. Therapeutic Advances in Gastroenterology. 10:132-41. One of three contributing authors, Impact factor 5

Sandler C, Goldstein D, Horsfield S, Bennett BK, Friedlander M, Bastick PA, Lewis CR, Segelov E, Boyle FM, Chin MTM, Barry BK, Webber K, Lloyd AR. 2017. Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue. Journal of Pain and Symptom Management. 54:74-84. contributing author, Impact factor 2.6

Strosberg J, Halfdanarson T, Bellizzi A, Chan J, Dillon J, Heaney A, Kunz P, O’Dorisio T, Salem R, Segelov E, Howe J, Pommier R, Brendtro K, Mohammad Bashir M, Singh S, Soulen M, Tang L, Zacks J, Yao J, Bergsland E. The North American Neuroendocrine Society (NANETS) Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 46:707-14. contributing author, Impact factor 2.7

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JFG, Anson-Cartwright L, Chung PWM, Warde PR, Moore MJ, Bedar PL, Tran B. (in press). Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumours. Clin Genitourin Cancer. doi: 10.1016/j.clgc.2017.08.012

Templeton DJ, Roberts JM, Poynten IM, Law C, Hillman RJ, Farnsworth A, Fairley CK, Tabrizi SN, Grulich AE, Jin F, Acraman B, Carr A, Carroll S, Cooper D, Cornall A, Crampton L, Fairley K, Feeney L, Fraissard E, Howard K,  & SPANC Study Team (Law M, Machalek DA, McCaffery K, McGrath P, Mellor R, Norris R, O'Dwyer M, Pendlebury S, Petoumenos K, Phillips S, Poynten IM, Prestage G, Richards ., Schema L, Seeds D,  Segelov E, Templeton M, Thurloe, JK, Tong WWY, Varma R. 2017. Prevalence and predictors of unsatisfactory anal cytology tests in a cohort of gay and bisexual men in Sydney, Australia: Baseline findings from the Study of the Prevention of Anal Cancer (SPANC). European Journal of Cancer Prevention. 26:212-16

Martinez- Chacon G, Brown KA, Docanto MM, Kumar H, Salminen S, Saarinen N, Mäkelä S. IL-10 suppresses TNF-α-induced expression of human aromatase gene in mammary adipose tissue.FASEB J.2018 Jun:32(6):3361-3370

To SQ, Kwan EM, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhöfer T, Azad AA. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Jun;73(6):818-821.

Au CC, Docanto MM, Zahid H, Raffaelli FM, Ferrero RL, Furness JB, Brown KA. Des-acyl ghrelin inhibits the capacity of macrophages to stimulate expression of aromatase in breast adipose stromal cells.J Steroid Biochem Mol Biol. 2017 Jun;170:49-53

To SQ, Kwan EM, Fettke H, Mant A, Docanto M, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhöfer T, Azad AA (2018). “AR-V7 or AR-V9 expression in whole blood does not predict response to androgen-axis targeting agents in metastatic castration-resistant prostate cancer”. European Urology. Jun;73(6):818-821

Ho SM, Rao RC, To SQ, Schoch E and Tarapore P (2017). “Bisphenol A and its analogues disrupt centrosome cycle and microtubule dynamics in prostate cancer”. Endocrine Related Cancer. Feb;24(2):83-96

Nilotinib dose-optimisation in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Hughes T, Munhoz E, Aurelio Salvino M, Ong TC, El-Haddad A, Shortt J, Quach H, Pavolovsky C, Louw V, Shih, L-Y, Turkina A, Meillon L, Jin Y, Acharya S, Dalal D, Lipton G. Br J Haematol2017; 179: 219-228. Citations: 1

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Fox LC, Cummins KD, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan K-L, Hsu W-H, Ashraf A, Putt F, Grigg A. Blood Adv 2017; 1: 602-11.

Genomic characterisation of Eµ-Myc lymphomas by massively-parallel sequencing identifies Bcor as a MYC co-operative tumor-suppressor gene. Lefebure M, Tothill RW, Kruse E, Hawkins ED, Shortt J, Matthews GM, Gregory GP, Martin BP, Madison JK, Todorovski I, Doyle MA, Lupat R, Li J, Schroeder J, Wall M, Craig S, Poortinga G, Cameron D, Bywater M, Kats L, Gearhart MD, Bardwell V, Dickins RA, Hannan RA, Papenfuss T, Johnstone RW. Nature Commun2017; 8: 14581. Citations: 2

BET-bromodomain inhibitors engage the host immune system and regulate the expression of the immune checkpoint ligand PDL1. Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Sadovnik I, Bauer K, Valent P, Traunbauer AK, Bradner JE, Zuber J, Shortt J*& Johnstone RW*. Cell Rep 2017; 18: 2162-74. *co-senior authors. Citations: 18

A chemical probe toolbox for dissecting the cancer epigenome. Shortt J*, Ott CJ*, Johnstone RW & Bradner JE. Nat Rev Cancer2017; 17: 160-83. *co-first authors. Citations: 19 This invited review was featured as a cover illustration in Nat Rev Cancer.

High rates of potentially infectious exposures between immunocompromised patients and their companion animals: An unmet need for education. Gurry G, Campion V, Premawardena C, Woolley I, Shortt J, Bowden D, Kaplan ZS & Dendle C. Int Med J2017; 47: 333-35. Citations 1

For 2016 publications click here

Department Abstracts


E. Segelov, D. Williams, J. Chia, O. Sieber. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. (2018): 695-695.

Segelov E, Williams D, Chia J, Sieber O. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. Journal Clinical Onc 36 (4_suppl), 695-695.

Clarke S, Burge M, Feeney K, Jones K, Gibbs P, Molloy M,Marx G, Price T, Reece W, Segelov E, Tebbutt N. Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab. Journal Clinical Onc 36 (4_suppl), 719-719. Presented at ASCO GI 2018.

P. Blinman, D. Goldstein, A. Martin, M. Jefford, D. Boadle, N. Tebbutt, J. Paul, A. Haydon, E. Segelov, M. Stockler. Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? J Clin Oncol (2018) 36:15_suppl: 3602-3602.

Singh S, Bergsland E, Card C, Hope T, Kunz P, Ladiley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus, IASLC 19th World Conference on Lung Cancer Sept 2018, Toronto.

Segelov E, Bergsland E, Card C, Hope T, Kunz P, Ladiley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Singh S. Pulmonary Neuroendocrine (Carcinoid) Tumors: The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET), European Society of Medical Oncology, Oct 2018, Munich.

J. L. Gulley, M. Borre, N. J. Vogelzang, S. Ng, N. Agarwal, C. C. Parker, D. W. Pook, P. Rathenborg, T. W. Flaig, J. Carles, N. D. Shore, L. Chen, C. R. Heery, W. R. Gerritsen, F. Priou, P. W. Kantoff. Results of PROSPECT: A randomized phase 3 of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. J Clin Oncol (2018) 36:15_suppl, 5006-5006.

M. Michael, D. W. Pook, V. Ganju, E. Link, G. C. Toner, R. J. Hicks, A. Matera, M. Thompson, C. Cullinane, I. Campbell, M. Burge, C. S. Karapetis. The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study. J Clin Oncol 36, 2018 (suppl; abstr 2563).

J. Desai, M. Voskoboynik, B. Markman, J. Hou, D. Zeng, T. Meniawy. Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclona antibody bgb-A333 alone and in combination with anti-PD-monoclonal antibody tislelizumab in patients with advanced solid tumors. J Clin Oncol 36, 2018 (suppl; abstr TPS3113).


Segelov E, Earle C, Venook A, Saskin R, Mofid L, Singh S. 2017. Survival by sidedness of metastatic colorectal cancer (mCRC) treated with Epidermal Growth Factor Receptor Antibodies (EGFR-Ab) in the refractory setting: a population-based study of 1509 patients. Annals of Oncology 28.suppl_5.

Singh S, Moody L Chan DL, Metz D, Strosberg J, Segelov E. 2017. Follow up recommendations for completely resected Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Consensus Guidelines from the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with the North American Neuroendocrine Tumour Society (NANETS). Annals of Oncology 28.suppl_5 (2017)

Chan DL, Segelov E, Moody L, Liu N, Fischer H, Austin P, Singh S. 2017. Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study. Annals of Oncology 28.suppl_5

Shapiro J, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M, Wasan H, Ciardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, Segelov E. 2017. The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with “Quad WT”. J Clin Oncol 35 (15) 3572.

Segelov E, Chan DL, Moody L, Metz D, Strosberg J, Singh S. 2017. Development of follow up recommendations for completely resected Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS). ASCO GI 2017 (oral presentation). Journal Clin Onc (2017): 424-424.

Chan DL, Segelov E, Ferone D, Albertelli M, Singh S. 2017. Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review. Journal Clin Onc (2017): 422-422

Moody L, Segelov E, Chan D. Carsley S, Strosberg J, Metz D, Singh S. 2017. Optimising followup after complete surgical resection of Gastrointestinal Neuroendocrine Tumours- a Delphi process to produce expert consensus in an area lacking clinical evidence. NEUROENDOCRINOLOGY, vol. 105, pp. 336-336. Neuroendocrinology 2017.105: 336-336.

Segelov E, Chan DL, Moody L, Metz D, Strosberg J, Singh S. 2017. Follow-up in resected gastroenteropancreatic neuroendocrine tumours. AGITG Annual Scientific Meeting, Cairns 2017.

J. Desai, B. Markman, S. Ananda, N. C. Tebbutt, M. Michael, B. J. Solomon, G. A. McArthur, J. Lundy, E. M. Kwan, P. M. Waring, B. Tran. (2017). A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study. J Clin Oncol 35, 2017 (suppl; abstr 3557)

Poon P, Shaw T, Franco M, Runacres F, William L, Yoong J. Successful large volume ‘lymphocentesis’ for refractory lymphoedema in lower and upper limbs. Internal Medicine Journal. 2017 May 1;47(5):607-.

Hugo, H. J., Gunasinghe, N. P. A. D., Hollier, B. G., Tanaka, T., Blick, T., Toh, A., Hill, P., Gilles, C., Waltham, M., Thompson, E. W. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin. 2017 July, 27. BREAST CANCER RESEARCH, vol. 19, no. 86.

Lee B, Cohen J, Lipton L, Tie J, Javed A, Li , Goldstein D, Cooray P, B Nagrial A, Burge M, Tebbutt N, Nikfarjam M, Harris M, O’Broin-Lennon, Wolfganag C, TomasettiC, Papadopoulos NJ, Kinzler K, Vogelstein B, Gibbs P. Potential role of circulating tumour DNA( ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer. ASCO GI 2017 Abs 4101

Cubillo A, dean A, Munoz A, Pazo Cid R, Martin M, Mercade T, Lipton L, Harris M, Santasusana J, Gullen C, Tebbutt N, Cooray P, Sohal D, Zalupski M, Kolevska T, Stagg R , Holmgren E, Goldstein D. Yosemite : A 3 arm Double blind randomised Phase 2 study of Gemcitabine , Abraxane amd Placebo versus Gemcitabine , Abraxane and either 1 or 2 truncated courses of Demcizumab .620 PD ESMO 2017

Jong I, Croagh D, Harris M, Bradney M. Biodistribution of implanted phosphorus -32 into unresectable locally advanced pancreatic adenocarcinoma given in combination with gemcitabine +nab-paclitaxel chemotherapy – A single centre experience. World Federation of Nuclear Medicine and Biology Congress 2018 Abstract 1745. Accepted December 2017



 Updated July 2018

Refer A Patient 

Symptom and Urgent Review Clinic (SURC)

The SURC clinic in Dandenong will be in operation from Monday the 5th of February 2018. If you require a patient referral to the SURC pharmacist or nurse, please call the team via phone on 0435 960 916 or email

McGarth Foundation Breast Cancer Nurse

Dandenong Hospital has welcomed its first McGrath Foundation Breast Care Nurse in Feburary 2018 and is offering free support to patients and their families - complete care programs including support groups & emotional resilience worskops are available.

Please contact Katie Evans via phone on 0466 014 350 or email her at 

Conference Participation

ESMO Asia 2017


Optimal Care Pathways
for Cancer Patients

The optimal cancer care pathways (OPS) describe the optimal cancer care for specific tumour types. They map the patient journey, aiming to foster an understanding of the whole pathway and its components to promote quality cancer and patient experiences.

Cancer: What to Expect?

Information for patients  

Information for Clinicians

McGrath Foundation Breast Cancer Nurse


Cancer Prevention

Between 30-50% of all cases are preventable. Prevention offers the most cost-effective long-term strategy for the control of cancer. National policies programmes should be implemented to raise awareness, to reduce exposure to cancer risk factors and to ensure that people are provided with the information and support they need to adopt healthy lifestyles.

Cancer Prevention Link